Johnson & Johnson completes two new plants in China
(from left) Joaquin Duato, vice chairman of the Johnson & Johnson Executive Committee; Will Song, chairman of Johnson & Johnson China; and Paul Stoffels, Johnson & Johnson chief scientific officer and vice chairman of the Executive Committee. The group was present for the J&J China Innovation Powerhouse Initiative.
Health-care and medical device giant Johnson & Johnson announced the completion of two manufacturing plants with a combined investment of US$577 million on Wednesday as part of its J&J China Innovation Powerhouse initiative.
The company reaffirms its commitment to bringing innovative products and services to China, and partnering with local stakeholders to further drive innovation and improve health for people in China and around the world.
"Innovation is not only the core strength of Johnson & Johnson’s global business, but also the key growth driver of Johnson & Johnson's rapid development in China for more than 30 years,” commented Joaquin Duato, vice chairman of the Executive Committee of Johnson & Johnson.
The Janssen Pharmaceutical Companies of Johnson & Johnson launched a US$397-million plant in Xi'an, which is expected to reach an annual production capacity of 4 billion tablets and capsules, and up to 57 million tubes of cream.
Its automation and advanced supply chain is expected to expedite technological innovation and drug launches, helping to serve the rapidly expanding needs of the country and other markets in the region.
“Our businesses across medical devices, pharmaceuticals and consumer health have achieved double-digit growth in China over the last year and we look forward to continuing our partnership with the government and industry partners to further drive innovation to benefit patients and consumers in China and around the world," said Will Song, chairman of Johnson & Johnson China.
Johnson & Johnson Medical Devices Companies' new surgical devices plant, with a US$180-million investment, is located in Suzhou Industrial Park and is also expected to go into production by the end of 2019.
It will become part of an integrated medical technology campus in Suzhou which also includes an existing orthopaedic medical devices factory and an R&D center, bringing manufacturing, R&D, shared services and technology innovation in one place.
A separate memorandum of understanding was also reached between J&J's Lung Cancer Initiative and Chinese Association on Tobacco Control (CATC) to collaborate on ways to enhance smoking cessation education with the goal of providing innovation health care solutions to current smokers and patients.
